Stand Up to Cancer
Tracked across 2 events · 27 articles · First seen Nov 07, 2025 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
The phase 2 EVITA trial, a randomized, double-blind, placebo-controlled study, tested whether high-dose oral vitamin C (1000 mg/day for 12 months) could benefit patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies, conditions…
Impact: Its VAI-SU2C Epigenetics Dream Team helped lead the trial, supporting its mission of accelerating cancer research.
Sep 21, 2026 · 6 articles
Tech
Impact: Co-funder through a translational research grant; supports innovative cancer interception approaches.
Jul 16, 2026 · 21 articles
40
Stand Up to Cancer led trialEVITA Vitamin C Blood Cancer Trial
ERGEN INTELLIGENCE
Track Stand Up to Cancer live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard